Awarded
DERMOCORTICOIDE D'ACTIVITE MODEREE (GROUPE II)
Original language: French
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
- Buyer
- CHU Lyon
- Winners
- ALLIANCE PHARMA FRANCE
- Contract value
- €35,024
- Published
- 14 Jan 2026
- Awarded
- 12 Dec 2025
- Contract start
- 12 Dec 2025
- Contract end
- 31 May 2027stated
- Region
- Rhône
More awards from this buyer
| Awarded | Buyer | Winner | Contract value | Published |
|---|---|---|---|---|
| OMALIZUMAB | CHU Lyon | CELLTRION HEALTHCARE FRANCE SAS | €220,320 | 14 Jan 2026 |
| BETA 2 STIMULANTS INHALES TRES LONGUE DUREE D'ACTION | CHU Lyon | NOVARTIS PHARMA SAS | €54,796 | 14 Jan 2026 |
| BETA 2 STIMULANTS + ANTICHOLINERGIQUE TRES LONGUE DUREE D'ACTION | CHU Lyon | GLAXOSMITHKLINE | €31,538 | 14 Jan 2026 |
| Némolizumab NEMLUVIO | CHU Lyon | GALDERMA INTERNATIONAL | €9,117,600 | 5 Nov 2025 |
| DOIGTIER 2 DOIGTS NON STERILE POLYETHYLENE | CHU Lyon | DIDACTIC | €28,553 | 3 Nov 2025 |
| DOIGTIER 2 DOIGTS NON STERILE POLYETHYLENE | CHU Lyon | DIDACTIC | €57,105 | 3 Nov 2025 |